摘要
目的:探讨长春瑞滨联合卡铂化疗对晚期肺癌的治疗效果和安全性。方法:选取我院肿瘤科收治的晚期肺癌患者60例,根据不同治疗方案分为实验组与对照组,每组各30例患者。比较两组患者治疗前后的CEA、CA50、CYFRA21-1水平、白细胞计数及T淋巴细胞亚群CD4+、CD8+水平的变化。结果:治疗前,两组患者的CEA、CA50、CYFRA21-1水平、白细胞计数及T淋巴细胞亚群CD4+、CD8+水平比较均无统计学差异(P>0.05)。治疗后,实验组的CEA、CA50、CYFRA21-1、CD8+水平均明显低于对照组,而白细胞计数及T淋巴细胞亚群CD4+、CD4+/CD8+水平均显著高于对照组,差异均具有统计学意义(P<0.05)。结论:与放疗相比,长春瑞滨联合卡铂化疗能显著提高晚期肺癌的疗效,且不降低患者的细胞免疫。
Objective： To investigate the clinical efficacy and safety of vinorelbine combined with carboplatin chemotherapy in the treatment of advanced lung cancer. Methods： 60 patients with advanced lung cancer were selected and randomly divided into the experimental group and control group according to different treatments, 30 cases in each group. The CEA, CA50, CYFRA21-1 levels,white blood cells count and T lymphocyte subsets CD4＋, CD8＋level were compared before and after treatment. Results： No statistically significant difference was found in the CEA, CA50, CYFRA21-1 levels, white blood cell count and T lymphocyte subsets CD4＋, CD8＋levels before treatment between two groups（P〉0.05）. Compared with the control group, the CEA, CA50, CYFRA21-1, CD8＋levels of experimental group were significantly lower after treatment（P〈0.05）, while the white blood cell count, CD4＋, CD4＋/CD8＋were significantly higher after treatment（P〈0.05）. Conclusion： Compared with radiotherapy, vinorelbine combined with carboplatin chemotherapy could significantly improve the clinical efficacy of advanced lung cancer and had no effect on the cellular immunity.
出处
《现代生物医学进展》
CAS
2015年第25期4923-4925,4941,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金面上项目(81173610)
